Finally, our results revealed that tamoxifen-resistant BrCa cells exhibiting mTOR hyperactivation could restore tamoxifen therapy sensitivity through ZDHHC22 overexpression. The gene discussed is MTOR; the disease is invasive breast carcinoma.